Arcus Biosciences Reports Third Quarter 2021 Financial Results and Provides an Update on our anti-TIGIT Domvanalimab

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. SPY
4. IBM
5. META
6. MU
7. ACN
8. NVDA
9. BLZE
10. PRIM

Go back to Arcus Biosciences Reports Third Quarter 2021 Financial Results and Provides an Update on our anti-TIGIT Domvanalimab
(NYSE: RCUS) Delayed: 28.18 +0.95 (3.49%)
Previous Close $27.23    52 Week High $ 
Open $26.72    52 Week Low $ 
Day High $28.27    P/E N/A 
Day Low $26.72    EPS $ 
Volume 1,553,990